View Older Stories View More Recent Stories
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.8% Yield
-
Piper Sandler on calls with diabetes clinicians
-
Piper Sandler: 'Abbott Labs (ABT) Remains Our Favorite Large-Cap Name'
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Gordon Haskett Comments Positively on Abbott (ABT)
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) 2500 contracts of July 127 calls trade, share price up 3.2%
-
Abbott Labs (ABT) PT Lowered to $155 at Citi
-
Abbott upgraded after post-earnings selloff, hardware drag seen temporary
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Lowered to $135 at Mizuho
-
Jefferies Upgrades Abbott Labs (ABT) to Buy
-
Abbott Labs (ABT) PT Lowered to $145 at BTIG
-
Abbott Labs (ABT) PT Lowered to $140 at Evercore ISI
-
Goldman Sachs Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY25 EPS Guidance
-
Abbott (ABT) option IV bid into quarter results
-
Abbott Labs (ABT) PT Raised at RBC Capital Following Recent Stock Performance
-
Piper Sandler Reiterates Overweight Rating on Abbott Labs (ABT)
-
TD Cowen Expects a 'Good 2Q' for Abbott Labs (ABT)
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT)
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
Oppenheimer on Abbott Labs (ABT): 'we have become incrementally bullish'
-
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
-
Leerink Partners Starts Abbott Labs (ABT) at Market Perform
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.7% Yield
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Tandem Diabetes (TNDM) partners with Abbott (ABT) for integration
-
Evercore ISI on Boston Scientific (BSX) Read-through: 'This should be a positive for ABT & MDT'
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Abbott (ABT) Receives FDA Approval for Tendyne
-
Abbott's (ABT) Libre Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Abbott (ABT) Active, Shares Up 4%
-
Medtech Q1 earnings preview: Potential tariff exposure
-
Abbott Labs (ABT) PT Raised to $144 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Raised to $145 at TD Cowen
-
Abbott Labs (ABT) PT Raised to $145 at RBC Capital, Citing 'Positive Business Fundamentals'
-
UBS Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Raised to $145 at Piper Sandler on "Organic Growth'
-
Abbott Labs (ABT) PT Raised to $145 at Stifel
-
Abbott Labs (ABT) PT Raised to $140 at Oppenheimer
-
Abbott Labs (ABT) PT Raised to $142 at Raymond James
-
Abbott Labs (ABT) PT Raised to $145 at BTIG
-
Abbott Labs (ABT) PT Raised to $137 at Jefferies
-
Abbott Labs (ABT) PT Raised to $140 at Evercore ISI
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Mizuho Reiterates Neutral Rating on Abbott Labs (ABT)

